Clinical trialNCT06179108CompletedPhase 2Interventional

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

SponsorLB Pharmaceuticals Inc.Enrollment359Schizophrenia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives of the study are to evaluate improvement in CGI-S, safety and tolerability, and pharmacokinetics.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

John Kane, MD
The Zucker Hillside Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Pillar Clinical Research
Bentonville, Arkansas, United States
Woodland Internation Research Group
Little Rock, Arkansas, United States
Woodland Research Northwest
Rogers, Arkansas, United States
Celexel Clinical Innovations
Bellflower, California, United States
Synexus
Cerritos, California, United States
Proscience Research Group
Culver City, California, United States
Celexel Cns
Garden Grove, California, United States
Synergy Research
Lemon Grove, California, United States
Cenexel Cit Riverside
Riverside, California, United States
Nrc Research Institute
Santa Ana, California, United States
Behavioral Clinical Research, Inc.
Hollywood, Florida, United States
Cenexel Rca
Hollywood, Florida, United States
Segal Institute for Clinical Research
Miami Lakes, Florida, United States
Cenexel Acmr
Atlanta, Georgia, United States
Cenexel Iresearch
Decatur, Georgia, United States
Pillar Clinical Research
Chicago, Illinois, United States
Uptown Research Institute
Chicago, Illinois, United States
Cenexel Cbh
Gaithersburg, Maryland, United States
Cenexel Hri
Berlin, New Jersey, United States
Richmond Behavioral Associates
Staten Island, New York, United States
Midwest Clinical Research Center
Dayton, Ohio, United States
Neuro-Behavioral Clinical Research
North Canton, Ohio, United States
Community Clinical Research
Austin, Texas, United States
Insite Clinical Research
DeSoto, Texas, United States
Pillar Clinical Research
Richardson, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

LB-102

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Nov 2023
Primary completion: 4 Dec 2024
Completion: 4 Dec 2024
Last update posted: 22 Oct 2025
Registered enrollment: 359
Registry id: NCT06179108

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.